KPV 5mg — Vial Spec, Reconstitution Math & COA

Overview of KPV (Lysine-Proline-Valine) in Laboratory Research

KPV is a tripeptide comprising the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH), represented chemically as Lys-Pro-Val (sequence H-Lys-Pro-Val-OH). Despite lacking the melanotropic pigment-inducing sequences present in full-length melanocortin peptides, KPV retains potent anti-inflammatory properties that make it a central subject of study in mucosal biology and cellular signaling.

Preclinical investigations focus primarily on the peptide's capacity to attenuate inflammatory cascades in intestinal epithelial cells and dermal tissues. In vitro models demonstrate that KPV is actively transported across cell membranes via the oligopeptide transporter PepT1 (SLC15A1). Once internalized, it modulates intracellular signaling pathways, notably inhibiting the nuclear translocation of Nuclear Factor kappa B (NF-κB). Researchers utilize the compound to probe targeted anti-inflammatory mechanisms without triggering broader systemic melanocortin receptor activation. To review PX1's complete range of analytical-grade sequences, examine our comprehensive PX1 peptide catalog.

PX1 Catalog Availability & Vial Configuration

Laboratory researchers frequently baseline their experimental dilution protocols using a 5mg target mass. While this guide provides precise reconstitution mathematics for a 5mg mass model, PX1 Research currently packages and distributes KPV in a standardized KPV 10mg vial format. The 10mg format offers superior economy and extended utility for multi-plate cell culture assays or longitudinal animal studies requiring identical lot numbers.

The physical characteristics of lyophilized KPV remain consistent across fill sizes. The compound is presented as a white, dense lyophilized cake sealed under inert nitrogen in an ISO-compliant USP Type I borosilicate glass vial with a fluoropolymer-coated chlorobutyl stopper. This packaging prevents moisture ingress and oxidative degradation, ensuring peptide stability prior to laboratory reconstitution.

Reconstitution Math: Diluent Volumes & Working Concentrations for 5mg Mass

Accurate concentration calculations are vital for reproducing published in vitro micro-molar dosing or calculating milligram-per-kilogram parameters in rodent models. When working with a hypothetical or legacy 5mg KPV mass, adding precise volumes of sterile diluent (such as Bacteriostatic Water or Sterile 0.9% Sodium Chloride) yields predictable stock concentrations.

For a 5mg lyophilized KPV vial, the resulting stock concentrations based on standard diluent additions are calculated as follows:

1.0 mL Diluent Addition: Yields a stock concentration of 5.0 mg/mL (5,000 µg/mL). At this concentration, 10 µL of stock solution contains exactly 50 µg of KPV peptide mass.

2.0 mL Diluent Addition: Yields a stock concentration of 2.5 mg/mL (2,500 µg/mL). At this concentration, 10 µL of stock solution contains 25 µg of KPV peptide mass.

3.0 mL Diluent Addition: Yields a stock concentration of 1.67 mg/mL (1,666.7 µg/mL). At this concentration, 10 µL of stock solution contains 16.67 µg of KPV peptide mass.

To perform rapid, error-free conversions for customized volume requirements or alternate vial sizes, researchers are encouraged to utilize the interactive reconstitution calculator.

Aliquot Planning & Volumetric Dosing in Preclinical Models

Repeated freeze-thaw cycles subject peptide chains to physical shearing and structural degradation, compromising experimental reproducibility. Therefore, proper aliquot planning immediately following reconstitution is essential for preserving chemical integrity over long-term study schedules.

Following initial solvent introduction and complete dissolution, stock solutions should be divided into single-use microcentrifuge aliquots using sterile, low-binding polypropylene tubes. Aliquot volumes should align with daily working requirements (e.g., 50 µL to 200 µL per vial). Once frozen at -20°C or -80°C, individual aliquots should be thawed once, utilized immediately for working dilutions in assay buffers, and discarded. Unused portions must not be refrozen.

Lot-Matched Certificate of Analysis (COA) Verification

PX1 Research maintains stringent analytical verification standards for every manufactured batch. Each lot of KPV undergoes rigorous independent laboratory evaluation prior to distribution. Research institutions can verify batch parameters directly through our public COA library.

Key analytical testing parameters included on every lot-matched COA comprise:

High-Performance Liquid Chromatography (HPLC): Confirms peptide purity levels exceeding 98.0%. HPLC chromatograms map chemical purity by measuring peak area percentage, ensuring freedom from baseline degradation products or truncated synthesis sequences.

Mass Spectrometry (MS): Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular mass. KPV has a theoretical monoisotopic molecular weight of approximately 383.48 g/mol, which must align precisely with observed mass spectrum peaks.

Endotoxin Testing: Quantitative Chromogenic LAL (Limulus Amebocyte Lysate) assays ensure endotoxin levels remain below 0.05 EU/mg. Low endotoxin limits are essential for avoiding false-positive immune responses in inflammatory pathway models.

Mechanism of Action: Intestinal Barrier & Inflammatory Pathway Modulation

Preclinical studies demonstrate that KPV exerts its primary biochemical effects by interacting with intracellular inflammatory networks. Unlike larger melanocortin peptides that act strictly via cell surface G-protein coupled receptors (MC1R–MC5R), KPV enters target cells—such as intestinal enterocytes and macrophages—via the PepT1 transporter.

In vitro data indicate that upon intracellular uptake, KPV inhibits the phosphorylation and nuclear translocation of the NF-κB p65 subunit. By blocking NF-κB activation, KPV downregulates the transcription of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. Furthermore, rodent models of dextran sulfate sodium (DSS)-induced colitis suggest that KPV administration supports epithelial barrier integrity by preserving tight junction protein expression (such as ZO-1 and Occludin), thereby reducing mucosal permeability under inflammatory stress. Further mechanistic research can be explored via the PX1 research hub.

Comparative Analysis: KPV vs. Related Epithelial & Anti-Inflammatory Compounds

When designing preclinical protocols investigating mucosal repair, cell migration, or gut barrier kinetics, researchers often evaluate KPV alongside alternative research compounds with overlapping research targets. While KPV acts primarily as an intracellular NF-κB modulator via PepT1 transport, compounds such as BPC-157 5mg operate through distinct angiogenic and growth factor signaling pathways to promote tissue healing. Concurrently, candidate peptides like Larazotide function directly as tight junction regulators to prevent macromolecular passage across intestinal membranes, while VIP modulates immune cell cytokine profiles via specific GPCR pathways. Selecting between these agents depends on whether the investigative target involves intracellular signal transcription, structural cell-junction assembly, or vascular remodeling.

Reconstitution Protocol & Solvent Selection

Executing proper reconstitution protocols ensures physical dissolution without inducing structural modifications. Researchers should adhere to standard aseptic laboratory practices when preparing KPV solutions:

1. Equilibrate the lyophilized vial to room temperature (15°C to 25°C) before reconstitution to prevent condensation inside the container.

2. Sanitize the rubber septum with an 70% isopropyl alcohol wipe.

3. Using a sterile syringe, draw the calculated volume of diluent (e.g., Bacteriostatic Water containing 0.9% benzyl alcohol for multi-use protocols, or sterile PBS for immediate cell culture applications).

4. Direct the diluent stream down the inner glass wall of the vial rather than shooting directly onto the lyophilized cake.

5. Allow the diluent to absorb into the powder naturally, then gently swirl the vial in a circular motion until completely clear. Do not vortex or agitate vigorously, as mechanical shear stress can cause peptide aggregation.

Long-Term Storage, Hydrolytic Stability & Handling

To maintain structural stability and prevent chemical degradation, KPV must be stored under controlled thermal conditions. Lyophilized powder should be stored at -20°C for short-to-medium term storage, or at -80°C for extended archival preservation. Under these conditions, the desiccated peptide remains stable for up to 24 months from the date of manufacture.

Once reconstituted into aqueous solution, KPV is susceptible to hydrolytic cleavage over time. Reconstituted stock solutions stored in bacteriostatic diluent at 2°C to 8°C should be utilized within 28 days. Solution aliquots stored at -20°C remain stable for up to 3 to 6 months. Exposure to direct ultraviolet light and elevated temperatures must be avoided at all times.

Bulk Sourcing & ISO 17025 Quality Assurance

PX1 Research caters to academic institutions, biotechnology organizations, and contract research organizations (CROs) requiring reliable lot-to-lot consistency. All compounds are synthesized in state-of-the-art USA-based facilities adhering to cGMP guidelines and validated through ISO 17025 accredited testing laboratories.

For high-throughput screening projects or large-scale animal study series, research accounts can secure custom batch sizes, bulk quantities, and dedicated analytical documentation through our wholesale portal. Orders placed Monday through Friday ship same-day from our distribution centers in California and Arizona.